Alberto Lleó Bisa

Alberto Lleó

Dr. Alberto Lleó is the director of the Memory Unit of the Neurology Department at Hospital de la Santa Creu i Sant Pau.

After obtaining his Medical degree from the University of Barcelona, he completed his specialization in Neurology at Hospital de la Santa Creu i Sant Pau in 2000. Two years later, he obtained his PhD in Medicine at the University of Barcelona and continued his education with a clinical and basic research fellowship on memory and movement disorders at the Massachusetts General Hospital, Boston (2002-2004) where he combined clinical and research tasks.

In his professional career, Dr. Alberto Lleó has combined his clinical activity with translational research projects in the field of dementias with a specific focus on the molecular bases of the disease and biomarker development. Some of his main contributions are the discovery of new genetic alterations in Alzheimer’s disease, the study of the gamma-secretase complex, and the assessment of new chemical biomarkers for Alzheimer’s disease and frontotemporal dementia.

Today, Dr. Alberto Lleó runs a translational group, leads many projects funded by public and private agencies, and collaborates regularly with numerous national and international research groups. He also coordinates the Alzheimer program of CIBERNED (Center for Networked Biomedical Research in Neurodegenerative Diseases). To date, he has authored more than 20 book chapters and over 150 publications in international journals, and his contributions have been awarded by the Spanish Society of Neurology.

Recent Publications

  1. Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests. Benejam, B, Videla, L, Vilaplana, E et al. Alzheimers Dement (Amst) 2020
    PMID:32613076

  2. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Fortea, J, Vilaplana, E, Carmona-Iragui, M et al. Lancet 2020
    PMID:32593336

  3. Active bilingualism delays the onset of mild cognitive impairment. Calabria, M, Hernández, M, Cattaneo, G et al. Neuropsychologia 2020
    PMID:32540266

  4. Annexin A5 prevents amyloid-β-induced toxicity in choroid plexus: implication for Alzheimer's disease. Bartolome, F, Krzyzanowska, A, de la Cueva, M et al. Sci Rep 2020
    PMID:32523019

  5. APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. Konijnenberg, E, Tijms, BM, Gobom, J et al. Alzheimers Res Ther 2020
    PMID:32460813

  6. Disease-Specific Changes in Reelin Protein and mRNA in Neurodegenerative Diseases. Lidón, L, Urrea, L, Llorens, F et al. Cells 2020
    PMID:32438605

  7. Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease. Vilaplana, E, Rodriguez-Vieitez, E, Ferreira, D et al. Neurology 2020
    PMID:32291295

  8. Downregulation of miR-335-5P in Amyotrophic Lateral Sclerosis Can Contribute to Neuronal Mitochondrial Dysfunction and Apoptosis. De Luna, N, Turon-Sans, J, Cortes-Vicente, E et al. Sci Rep 2020
    PMID:32152380

  9. The Added Value of Tau-PET in the Assessment of Progressive Supranuclear Palsy. López-Mora, DA, Fernández León, A, Lleó, A et al. Clin Nucl Med 2020
    PMID:32149810

  10. Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. Westwood, S, Baird, AL, Anand, SN et al. J. Alzheimers Dis. 2020
    PMID:31985466

  11. CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. Faura, J, Bustamante, A, Penalba, A et al. J. Alzheimers Dis. 2020
    PMID:31958084

  12. Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. van der Lee, SJ, Conway, OJ, Jansen, I et al. Acta Neuropathol. 2020
    PMID:31955222

  13. A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. Stamate, D, Kim, M, Proitsi, P et al. Alzheimers Dement (N Y) 2019
    PMID:31890857

  14. Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. Rosas, I, Martínez, C, Clarimón, J et al. Neurobiol. Aging 2020
    PMID:31810584

  15. Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimer's Disease. Cantero, JL, Atienza, M, Lage, C et al. Cereb. Cortex 2020
    PMID:31799623

Search PubMed